MedXY News - atezolizumab

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial

By MedXY|Jul 14, 2026

The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, unde

atezolizumab

Latest news

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial

A Body Surface Area–Adjusted Bevacizumab Target Was Linked to Better Survival in Atezolizumab-Treated Unresectable Hepatocellular Carcinoma

Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial

Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma

Comparative Effectiveness and Safety of PD-L1 Inhibitors with Chemotherapy in Extensive-Stage Small Cell Lung Cancer: Insights from a French Nationwide Cohort Study

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Translating Precision Oncology into Improved Outcomes

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

Cabozantinib Plus Atezolizumab in mCRPC: CONTACT-02 Phase 3 Final Results and Clinical Implications